Alcon Inc. (ALC)’s TRYPTYR Wins FDA Nod for Dry Eye Disease

Alcon Inc. (NYSE:ALC) has announced that the U.S. Food and Drug Administration (FDA) has approved TRYPTYR (acoltremon ophthalmic solution) 0.003% for the treatment of signs and symptoms of Dry Eye Disease (DED), marking a major milestone for Alcon Inc. (NYSE:ALC) and patients alike.

TRYPTYR is the first-in-class TRPM8 receptor agonist eye drop, designed to rapidly stimulate natural tear production by targeting corneal sensory nerves, a novel approach for DED management.

A healthcare professional wearing a health communications device discussing patient data with a colleague.

In pivotal Phase 3 trials (COMET-2 and COMET-3), TRYPTYR demonstrated a significant increase in natural tear production as early as Day 1, with up to four times more patients achieving at least a 10mm increase in tear production at Day 14 compared to placebo (42.6% vs 8.2% in COMET-2; 53.2% vs 14.4% in COMET-3). These results were consistent through Day 90, highlighting its rapid and sustained efficacy.

With nearly 38 million Americans affected by DED but less than 10% receiving prescription treatment, TRYPTYR addresses a critical unmet need, especially given the dissatisfaction and slow onset associated with existing therapies. Alcon Inc. (NYSE:ALC) expects to launch TRYPTYR in the U.S. in the third quarter of 2025.

While we acknowledge the potential of ALC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than ALC and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.